VBI-1901

Phase 2Biologic

VVBI Vaccines Inc.

VBI-1901 is one of 9 biologic programs targeting Recurrent. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecurrentRecruiting

RecurrentPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Recurrent

#DrugCompanyPhaseTrials

Xiaflex

GGrupo Espanol de Tumores Neuroendocrinos

Approved

1 2

Certolizumab

Johnson & Johnson

Phase 3

1 3

Lu-PSMA I&T

MMedical University of Vienna

Phase 2

1 4

Anti-PD-1 Monoclonal Antibody

IiTeos Therapeutics

Phase 1

1 5

Photofrin

PPinnacle Biologics Inc.

Preclinical

1 6

Cordarone

WWyeth-Lederle Vaccines

Preclinical

1 7

VBI-1901

VVBI Vaccines Inc.

Phase 2

1 8

Ptvg-HP

UUniversity of Wisconsin, Madison

Phase 1

1 9

CART-EGFR-Il13ra2 Cells

UUniversity of Pennsylvania

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent1 trial

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting·VVBI Vaccines Inc.·Phase 1/2·NCT03382977·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VBI-1901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VBI-1901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VBI-1901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VBI Vaccines Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: VVBI Vaccines Inc.

VBI-1901

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent1 trial

References

Drug Info

Quick Facts

Related News